Chengdu Easton Biopharmaceuticals Co., Ltd.

SHSE:688513 Stock Report

Market Cap: CN¥7.2b

Chengdu Easton Biopharmaceuticals Future Growth

Future criteria checks 4/6

Chengdu Easton Biopharmaceuticals is forecast to grow earnings and revenue by 22.2% and 23% per annum respectively. EPS is expected to grow by 22.1% per annum. Return on equity is forecast to be 12% in 3 years.

Key information

22.2%

Earnings growth rate

22.1%

EPS growth rate

Pharmaceuticals earnings growth19.0%
Revenue growth rate23.0%
Future return on equity12.0%
Analyst coverage

Low

Last updated23 Apr 2024

Recent future growth updates

No updates

Recent updates

Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems

May 01
Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems

Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion

Mar 26
Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion

Earnings and Revenue Growth Forecasts

SHSE:688513 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,272457N/A7141
12/31/20251,771362N/A5543
12/31/20241,454291N/A5861
3/31/20241,154241152314N/A
12/31/20231,117227100275N/A
9/30/20231,1232452208N/A
6/30/20231,150243-25179N/A
3/31/20231,179254-90148N/A
12/31/20221,171247-187152N/A
9/30/20221,147242-243145N/A
6/30/20221,100250-197181N/A
3/31/20221,071243-236157N/A
12/31/20211,023232-123148N/A
9/30/20211,02323926225N/A
6/30/2021986209-61163N/A
3/31/2021967191-11165N/A
12/31/2020922178-42157N/A
9/30/2020942139-11680N/A
6/30/2020907115-45112N/A
3/31/2020886100-17118N/A
12/31/201994710946142N/A
12/31/201876913590167N/A
12/31/201747664N/A86N/A
6/30/201625044N/A77N/A
3/31/201624541N/A64N/A
12/31/201524138N/A51N/A
1/1/201520929N/A47N/A
12/31/201316215N/A28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688513's forecast earnings growth (22.2% per year) is above the savings rate (2.9%).

Earnings vs Market: 688513's earnings (22.2% per year) are forecast to grow slower than the CN market (24.2% per year).

High Growth Earnings: 688513's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688513's revenue (23% per year) is forecast to grow faster than the CN market (14.7% per year).

High Growth Revenue: 688513's revenue (23% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688513's Return on Equity is forecast to be low in 3 years time (12%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.